医学
癌症研究
单克隆抗体
横纹肌肉瘤
细胞毒性
嵌合抗原受体
免疫毒素
结合
抗体
体内
抗体-药物偶联物
抗原
体外
癌症
乳腺癌
细胞
受体
免疫结合物
免疫疗法
细胞培养
单克隆
癌细胞
肿瘤细胞
人源化抗体
作者
Meijie Tian,Katrina Jia,Jerry T. Wu,Adam Cheuk,Siteng Fang,Victor T. Ojo,Eleanor G. Pope,David Milewski,Yong Yean Kim,Hsien-Chao Chou,Avani Kelekar,Soumili Dey,Yunkai Yu,Mohammad Asikur Rahman,R.M. Naseer Khan,Oluwatobi T. Arisa,William Douglas Figg,Shyam K. Sharan,Zoë Weaver Ohler,Ludmila Szabova
标识
DOI:10.1016/j.xcrm.2026.102922
摘要
Compared with chimeric antigen receptor (CAR) T cell therapy, antibody-drug conjugates (ADCs) offer distinct advantages. Here, we report on two FGFR4-targeted ADCs, using the high-affinity monoclonal antibody 3A11, the same binder used in a CAR T cell format that is being evaluated at the NCI (NCT06865664) for patients with relapsed/refractory rhabdomyosarcoma (RMS). These ADCs, conjugated to monomethyl auristatin E (MMAE) or an exatecan derivative, are rapidly internalized, causing potent fibroblast growth factor receptor 4 (FGFR4)-dependent cytotoxicity in vitro. In subcutaneous RMS xenograft models, both ADCs demonstrated robust anti-tumor activities, significantly prolonging survival. Notably, exatecan-ADC showed better efficacy, with durable tumor control, in aggressive fusion-negative (FN) RMS559 and fusion-positive (FP) RH4 RMS cell-line-derived xenografts (CDXs) and a patient-derived RMS xenograft (PDX). Furthermore, exatecan-ADC effectively controls tumors in an FGFR4-expressing MDA-MB-453 breast cancer mouse model, eradicating relapsed tumors with retreatment. These findings highlight FGFR4-targeted ADCs as potent therapeutic agents against aggressive FGFR4-expressing malignancies, supporting their further clinical development.
科研通智能强力驱动
Strongly Powered by AbleSci AI